Why low line losses are especially important in early-phase clinical trials
Early-phase sterile fill-finish programmes often rely on limited quantities of valuable drug substance. Low line losses help maximise finished units, reduce API waste and improve clinical supply confidence. By combining efficient process design, Grade A isolator technology and experienced technical oversight, Eramol helps sponsors protect valuable material while supporting high-quality aseptic processing, terminal sterilisation and early-phase sterile manufacturing.
Why Low Line Losses Matter in Early-Phase Sterile Fill-Finish
Early-phase sterile fill-finish programmes often involve limited quantities of valuable drug substance, making product preservation just as important as manufacturing quality. Every millilitre lost during compounding, filtration, product transfer or filling can reduce the number of finished units available for clinical trials.
Low line losses help sponsors maximise manufacturing yield, protect scarce API, reduce unnecessary waste and improve confidence in clinical supply planning. This is particularly important for biologics, peptides, cell and gene therapies, rare disease medicines and other complex injectable products where replacement material may be costly or difficult to obtain.
Achieving low line losses requires more than advanced equipment. Facility design, efficient product transfer, Grade A isolator technology, optimised filling strategies and experienced technical oversight all play an important role in protecting valuable drug product while maintaining sterility assurance and regulatory compliance.
Eramol's early-phase sterile fill-finish capability has been developed specifically for clinical programmes where flexibility and product preservation are essential. Our integrated service combines <0.1% aseptic line losses, Grade A isolator-based processing, terminal sterilisation, QC testing, clinical packaging, UK and EU QP certification, storage and global distribution to help sponsors move efficiently from manufacture through to clinical trial supply with minimal product loss.
